Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Recordati reveals EMEA’s positive opinion of Silodyx and Urorec

Recordati reveals EMEA’s positive opinion of Silodyx and Urorec

23rd November 2009

Recordati revealed this week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended the granting of marketing authorisation for its drug brands Urorec and Silodyx.

This applies to 4 mg and 8 mg hard-capsule doses respectively for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Silodyx, which was originally developed by Kissei Pharmaceuticals, has been obtained under license by Recordati for the whole of Europe and for a further 18 nations in the Middle East and Africa.

The active substance in both products is silodosin – a urological medicinal product – which is a selective antagonist of the alfa 1A-adrenoreceptors.

Last month, Recordati revealed that its pharmaceutical revenues rose by 10.4 per cent during the first nine months of 2009.

Its consolidated revenue for the period reached 556.2 million euros (498.7 million pounds).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.